| Customization: | Available |
|---|---|
| Powder: | Yes |
| Customized: | Customized |
|
Still deciding? Get samples of $ !
Request Sample
|
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
| Product Name | Olaparib |
| Appearance | White Powder |
| CAS NO. | 763113-22-0 |
| Molecular Formula | C20H17FN4O2 |
| Storage | Keep in a cool, dry, dark location |
Olaparib, with the molecular formula C20H17FN4O2, is an orally active poly(ADP-ribose) polymerase (PARP) inhibitor. It belongs to a class of drugs known as PARP inhibitors, which are designed to block the activity of PARP enzymes involved in DNA repair.
Cancer Treatment: Olaparib is primarily used in the treatment of certain types of cancer, particularly those with mutations in DNA repair genes such as BRCA1 and BRCA2.
Monotherapy and Combination Therapy: It can be administered as a monotherapy or in combination with other chemotherapy drugs to enhance the effectiveness of treatment and potentially improve patient outcomes.
Maintenance Therapy: Following successful initial treatment, olaparib may be used as a maintenance therapy to prevent recurrence of the cancer.
DNA Repair Inhibition: Olaparib functions by inhibiting PARP enzymes, which are crucial for repairing single-strand breaks in DNA. By blocking this repair mechanism, the drug induces the accumulation of DNA damage, leading to cell death.
Synthetic Lethality: In cells with defective DNA repair pathways, such as those with BRCA mutations, olaparib creates a synthetic lethal effect, making the cells more susceptible to DNA damage and promoting their death.
Targeted Therapy: Unlike traditional chemotherapy, which affects both normal and cancerous cells, olaparib is a targeted therapy that specifically targets cells with DNA repair deficiencies, minimizing side effects on healthy tissue.
){kind=link}